vs
Day One Biopharmaceuticals, Inc.（DAWN）与Primis Financial Corp.（FRST）财务数据对比。点击上方公司名可切换其他公司
Primis Financial Corp.的季度营收约是Day One Biopharmaceuticals, Inc.的1.1倍（$45.6M vs $39.8M），Primis Financial Corp.净利率更高（16.0% vs -49.6%，领先65.6%）
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
Primis金融集团是一家总部位于美国的金融控股公司，运营多家全服务银行子公司，面向个人及企业客户提供存款、贷款、按揭、财富管理等多元化金融服务，核心业务覆盖美国中大西洋沿岸区域。
DAWN vs FRST — 直观对比
营收规模更大
FRST
是对方的1.1倍
$39.8M
净利率更高
FRST
高出65.6%
-49.6%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $39.8M | $45.6M |
| 净利润 | $-19.7M | $7.3M |
| 毛利率 | — | — |
| 营业利润率 | -60.9% | — |
| 净利率 | -49.6% | 16.0% |
| 营收同比 | -57.6% | — |
| 净利润同比 | -153.3% | 200.0% |
| 每股收益（稀释后） | $-0.19 | $0.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DAWNFRST
| Q1 26 | — | $45.6M | ||
| Q4 25 | — | $80.9M | ||
| Q3 25 | $39.8M | $41.0M | ||
| Q2 25 | $33.9M | $43.2M | ||
| Q1 25 | $30.8M | $58.7M | ||
| Q4 24 | — | $38.8M | ||
| Q3 24 | $93.8M | $37.3M | ||
| Q2 24 | — | $35.7M |
净利润DAWNFRST
| Q1 26 | — | $7.3M | ||
| Q4 25 | — | $29.5M | ||
| Q3 25 | $-19.7M | $6.8M | ||
| Q2 25 | $-30.3M | $2.4M | ||
| Q1 25 | $-36.0M | $22.6M | ||
| Q4 24 | — | $-26.2M | ||
| Q3 24 | $37.0M | $1.2M | ||
| Q2 24 | — | $3.4M |
营业利润率DAWNFRST
| Q1 26 | — | — | ||
| Q4 25 | — | 44.8% | ||
| Q3 25 | -60.9% | 21.3% | ||
| Q2 25 | -103.1% | 6.9% | ||
| Q1 25 | -133.5% | 41.9% | ||
| Q4 24 | — | -123.0% | ||
| Q3 24 | 31.6% | -3.1% | ||
| Q2 24 | — | 7.8% |
净利率DAWNFRST
| Q1 26 | — | 16.0% | ||
| Q4 25 | — | 36.5% | ||
| Q3 25 | -49.6% | 16.7% | ||
| Q2 25 | -89.4% | 5.6% | ||
| Q1 25 | -117.0% | 38.6% | ||
| Q4 24 | — | -100.3% | ||
| Q3 24 | 39.5% | 3.3% | ||
| Q2 24 | — | 9.6% |
每股收益（稀释后）DAWNFRST
| Q1 26 | — | $0.30 | ||
| Q4 25 | — | $1.19 | ||
| Q3 25 | $-0.19 | $0.28 | ||
| Q2 25 | $-0.29 | $0.10 | ||
| Q1 25 | $-0.35 | $0.92 | ||
| Q4 24 | — | $-0.95 | ||
| Q3 24 | $0.38 | $0.05 | ||
| Q2 24 | — | $0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $451.6M | $159.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.9M | $427.2M |
| 总资产 | $513.8M | $4.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DAWNFRST
| Q1 26 | — | $159.9M | ||
| Q4 25 | — | $143.6M | ||
| Q3 25 | $451.6M | $63.9M | ||
| Q2 25 | $453.1M | $94.1M | ||
| Q1 25 | $473.0M | $57.0M | ||
| Q4 24 | — | $64.5M | ||
| Q3 24 | $558.4M | $77.3M | ||
| Q2 24 | — | $66.6M |
股东权益DAWNFRST
| Q1 26 | — | $427.2M | ||
| Q4 25 | — | $422.9M | ||
| Q3 25 | $450.9M | $382.2M | ||
| Q2 25 | $460.8M | $376.4M | ||
| Q1 25 | $479.5M | $375.6M | ||
| Q4 24 | — | $351.8M | ||
| Q3 24 | $555.5M | $381.0M | ||
| Q2 24 | — | $376.0M |
总资产DAWNFRST
| Q1 26 | — | $4.3B | ||
| Q4 25 | — | $4.0B | ||
| Q3 25 | $513.8M | $4.0B | ||
| Q2 25 | $519.0M | $3.9B | ||
| Q1 25 | $534.4M | $3.7B | ||
| Q4 24 | — | $3.7B | ||
| Q3 24 | $600.8M | $4.0B | ||
| Q2 24 | — | $4.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | — |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DAWNFRST
| Q1 26 | — | — | ||
| Q4 25 | — | $10.8M | ||
| Q3 25 | $-5.8M | $-11.4M | ||
| Q2 25 | $-24.8M | $-41.0M | ||
| Q1 25 | $-59.0M | $34.4M | ||
| Q4 24 | — | $19.5M | ||
| Q3 24 | $50.8M | $6.1M | ||
| Q2 24 | — | $52.3M |
自由现金流DAWNFRST
| Q1 26 | — | — | ||
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $-24.8M | — | ||
| Q1 25 | $-59.3M | — | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | $50.0M | — | ||
| Q2 24 | — | — |
自由现金流率DAWNFRST
| Q1 26 | — | — | ||
| Q4 25 | — | 11.2% | ||
| Q3 25 | — | — | ||
| Q2 25 | -73.2% | — | ||
| Q1 25 | -192.8% | — | ||
| Q4 24 | — | 47.3% | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | — | — |
资本支出强度DAWNFRST
| Q1 26 | — | — | ||
| Q4 25 | — | 2.1% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | 0.8% | 0.0% | ||
| Q2 24 | — | 0.0% |
现金转化率DAWNFRST
| Q1 26 | — | — | ||
| Q4 25 | — | 0.36× | ||
| Q3 25 | — | -1.67× | ||
| Q2 25 | — | -16.82× | ||
| Q1 25 | — | 1.52× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.37× | 4.93× | ||
| Q2 24 | — | 15.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
